Angelini Ventures invests into extended €75.8 million Series C financing round for Nouscom to advance neoantigen cancer vaccines
Amount Raised
$75.8 Million
Round Type
Series C
BaselBiotechnologyHealth CareTherapeuticsInvestors
Description
Angelini Ventures joins the syndicate of top-tier international healthcare investors in Nouscom’s Series C financing round, adding €7 million to the oversubscribed financing round, bringing the total raised to €75.8 million. This funding will enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof-of-concept endpoints.
Who to call at Nouscom, and when
A new round usually means Nouscom is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nouscom raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nouscom, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nouscom. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nouscom raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nouscom raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.